The prognostic impact of corticosteroid therapy for patients with tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) still remains unclear. This study aimed to evaluate the clinical impact and lymphocyte kinetics of corticosteroid administration for CRS in 45 patients with relapsed and/or refractory B-cell lymphoma treated with tisa-cel. This was a retrospective evaluation of all consecutive patients diagnosed with relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma with histologic transformation to large B-cell lymphoma, or follicular lymphoma who received commercial-based tisa-cel treatment. The best overall response rate, complete response rate, median progression-free survival (PFS), and median overall survival (OS) were 72.7%, 45.5%, 6.6 months, and 15.3 months, respectively. CRS (predominantly grade 1/2) occurred in 40 patients (88.9%), while ICANS (all grade) occurred in 3 patients (6.7%). No grade 3 or higher ICANS occurred. Patients with high-dose (≥ 524 mg, methylprednisolone equivalent, n = 12) or long-term (≥ 8 days, n = 9) corticosteroid use had inferior PFS and OS to patients with low or no corticosteroid use (both p < 0.05). The prognostic impact remained even in 23 patients with stable (SD) or progressive disease (PD) before tisa-cel infusion (p = 0.015) but not in patients with better disease status (p = 0.71). The timing of corticosteroid initiation did not have a prognostic impact. Multivariate analysis revealed that high-dose or long-term corticosteroid use were the independent prognostic factors of PFS and OS, respectively, after adjusting for elevated LDH before lymphodepletion chemotherapy and disease status (SD or PD). Lymphocyte kinetics analysis demonstrated that after methylprednisolone administration, the proportion of regulatory T-cells (Tregs), CD4+ central memory T (TCM) cells, and NK-cells were decreased, while that of CD4+ effector memory T (TEM) cells was increased. Patients with the higher proportion of Tregs at day 7 had a lower incidence of CRS, but this did not affect prognosis, indicating that early elevation of Tregs may serve as a biomarker for CRS development. Furthermore, patients with the higher number of CD4+ TCM cells and NK-cells at various time points had significantly better PFS and OS, whereas the number of CD4+ TEM cells did not impact prognostic outcomes. This study suggested that high-dose or long-term corticosteroid use attenuates the efficacy of tisa-cel, especially in patients with SD or PD. Additionally, patients with the high level of CD4+ TCM cells and NK-cells after tisa-cel infusion have longer PFS and OS.